![](https://rutherford-public-images.imgix.net/channels/logo_images/c62d4e36ab8e56a5a12b1d310e73d01d.jpg?auto=format&fit=crop&h=112&w=112)
HTN:RDN
It answers frequently asked questions with the latest expert opinions, guideline summaries, and essential information for practical adoption in managing uncontrolled and resistant Hypertension.
Learn about patient selection, key evidence for safety, effectiveness, durability, and integrating Renal Denervation into your practice.
Supported by an educational grant from Medtronic.
![](https://rutherford-public-images.imgix.net/channels/page_images/2063b15ae1d23cd378b927f4328de37c.jpg?w=2048)
Latest Updates
What do the guidelines say?
![](https://reachora-public-thumbnails.imgix.net/uploaded/production/3cbab22a-9d29-4133-a8fb-e8495379b733.png?auto=format&dpr=1)
The guidelines upgraded Renal Denervation to class 2 , which means RDN can be used in certain patients with uncontrolled blood pressure
![HTN:RDN](https://rutherford-public-images.imgix.net/channels/logo_images/c62d4e36ab8e56a5a12b1d310e73d01d.jpg?auto=format&fit=crop&h=16&w=16)
HTN:RDN
![](https://reachora-public-thumbnails.imgix.net/uploaded/production/48b6e0f9-2c1e-469b-94a9-1ed16a303ed7.png?auto=format&dpr=1)
The guidelines help us improve our practice, to fight the major problem in hypertension management which is poor patient adherence
![HTN:RDN](https://rutherford-public-images.imgix.net/channels/logo_images/c62d4e36ab8e56a5a12b1d310e73d01d.jpg?auto=format&fit=crop&h=16&w=16)
HTN:RDN
Safety, Significance, Sustainability
![](https://reachora-public-thumbnails.imgix.net/uploaded/production/6c518e24-6b5b-4f7e-98a6-8f7c43ff0ed1.png?auto=format&dpr=1)
Among all trials, renal denervation has achieved relevant reductions in blood pressure against the background of an excellent safety profile
![HTN:RDN](https://rutherford-public-images.imgix.net/channels/logo_images/c62d4e36ab8e56a5a12b1d310e73d01d.jpg?auto=format&fit=crop&h=16&w=16)
HTN:RDN
![](https://reachora-public-thumbnails.imgix.net/uploaded/production/7aa0b60e-80a1-425f-b6f3-c6cb905464e0.png?auto=format&dpr=1)
Five randomized controlled trials showed that denervation lowers blood pressure significantly
![HTN:RDN](https://rutherford-public-images.imgix.net/channels/logo_images/c62d4e36ab8e56a5a12b1d310e73d01d.jpg?auto=format&fit=crop&h=16&w=16)
HTN:RDN
![](https://reachora-public-thumbnails.imgix.net/uploaded/production/a42127cb-1874-4696-858f-febe0ab9b4ae.png?auto=format&dpr=1)
Across the studies, the overall message of benefit and sustained durability is the same
![HTN:RDN](https://rutherford-public-images.imgix.net/channels/logo_images/c62d4e36ab8e56a5a12b1d310e73d01d.jpg?auto=format&fit=crop&h=16&w=16)
HTN:RDN
Patient selection
![](https://reachora-public-videos.imgix.net/v/12/e/6/7153bc-aef7-4675-b068-0cfb96f49a5c/thumbnails/image_1.jpg?auto=format&dpr=1)
RDN:FDA | Patient Selection - An Interview with Dr. Taisei Kobayashi & Dr. Debbie Cohen
![HTN:RDN](https://rutherford-public-images.imgix.net/channels/logo_images/c62d4e36ab8e56a5a12b1d310e73d01d.jpg?auto=format&fit=crop&h=16&w=16)
HTN:RDN
![](https://reachora-public-thumbnails.imgix.net/uploaded/production/91bff76e-9378-49bc-b77f-b04e88ecb8f0.png?auto=format&dpr=1)
The consensus paper shows that the therapy works on the top of drugs, and in patients without drugs
![HTN:RDN](https://rutherford-public-images.imgix.net/channels/logo_images/c62d4e36ab8e56a5a12b1d310e73d01d.jpg?auto=format&fit=crop&h=16&w=16)
HTN:RDN
Patient Preference – Shared Decision Making
![](https://reachora-public-thumbnails.imgix.net/uploaded/production/335896c1-7130-46a0-8aa3-f3c8dd20ef49.png?auto=format&dpr=1)
We need to personalize the choice and to discuss case by case, what will be the best possible treatment
![HTN:RDN](https://rutherford-public-images.imgix.net/channels/logo_images/c62d4e36ab8e56a5a12b1d310e73d01d.jpg?auto=format&fit=crop&h=16&w=16)
HTN:RDN
Spakers
Rasha Al-Lamee
Dr Rasha Al-Lamee is an Interventional Cardiology Consultant at Imperial College Healthcare NHS...
Read More
Dr Rasha Al-Lamee is an Interventional Cardiology Consultant at Imperial College Healthcare NHS Trust in London, UK. Dr Al-Lamee’s research interests are complex coronary intervention, coronary physiology and invasive intravascular assessment. She designed, conducted and led the ORBITA trial and is the lead
author of the primary publication in The Lancet. At Imperial College, she is actively involved in the development and recruitment for a number of multi-centre clinical trials. Dr Al- Lamee has over 40 peer-reviewed publications and has presented at international Cardiology conferences worldwide throughout her clinical career. She studied at the University of Oxford and University College London. She went onto complete her training as a junior doctor on the Barts and the London Medical rotation before being appointed as a Specialist Registrar on the North West London Cardiology rotation in 2006.
Dr Al-Lamee has twelve years of Cardiology experience and completed three years of Interventional Fellowship training at Hammersmith Hospital in London. She also spent a year training as an Interventional Fellow under the supervision of Professor Antonio Colombo in Milan. She completed specialist training in Cardiology in 2013.
Show Less
David Kandzari
Doctor Kandzari is Director of Interventional Cardiology, Piedmont Heart Institute and Chief...
Read More
Doctor Kandzari is Director of Interventional Cardiology, Piedmont Heart Institute and Chief Scientific Officer, Piedmont Healthcare. He specializes in interventional cardiology, peripheral arterial disease and cardiovascular medicine.
Show Less
Felix Mahfoud
Professor Felix Mahfoud is an Associate Professor and senior physician of Internal Medicine and...
Read More
Professor Felix Mahfoud is an Associate Professor and senior physician of Internal Medicine and Cardiology at Saarland University Hospital, and Affiliate/Visiting Professor Harvard-MIT Biomedical Engineering, Institute of Medical Engineering and Science, Cambridge, US. Professor Mahfoud completed training in Cardiology and Interventional Cardiology at the Department for Internal Medicine III, Saarland University Hospital, Germany in 2014. Since 2017, he has served as Vice Chairman of the ‘Working Group on Interventional Hypertension Treatment’ for the European Society of Hypertension, and as a Committee Member of the 2018 Hypertension Guidelines.
Show Less
Atul Pathak
A consultant cadiologist at Clinique Pasteur, European excellence center for Hypertension,...
Read More
A consultant cadiologist at Clinique Pasteur, European excellence center for Hypertension, Toulouse, France. Features in 35 videos on Wondr Medical. Atul Pathak generally speaks on Hypertension and Renal Denervation (RDN).
Show Less
Andrew Sharp
Dr Sharp qualified from Edinburgh Medical School in 1998. He was appointed as a Consultant...
Read More
Dr Sharp qualified from Edinburgh Medical School in 1998. He was appointed as a Consultant Cardiologist at the Royal Devon and Exeter Hospital in 2011 and Honorary Associate Professor by the University of Exeter in 2018 before moving to the University Hospital of Wales in the summer of 2019.
He conducted his early training at the Royal Infirmary of Edinburgh, before moving to London for his senior clinical training. He completed the prestigious Milan-Imperial Interventional Cardiology Fellowship programme, having spent a year in San Raffaele and Columbus Hospitals, Milan, Italy, under the tutelage of Professor Antonio Colombo. He also spent three years training in interventional cardiology at St Mary’s Hospital and The Hammersmith Hospital (Imperial College Hospitals) in London.
Dr Sharp was awarded an MD postgraduate research degree from the University of Edinburgh for his work on the hypertensive heart and led a large research programme at the Royal Devon and Exeter Hospital, which he is now establishing in Wales. He has been Principal Investigator in more than 30 ethically-approved research trials since 2012 and has published extensively. He has an international reputation for leading the development of device-based treatments for hypertension (in particular that of renal denervation) and pulmonary embolism, as well as the advancement of intracoronary imaging and physiology.
Show Less
Faisal Shariff
Prof Faisal Sharif is Professor in Translational Cardiovascular Medicine and Innovation at NUI,...
Read More
Prof Faisal Sharif is Professor in Translational Cardiovascular Medicine and Innovation at NUI, Galway and a consultant Interventional Cardiologist for Galway University Hospitals. His research focuses on medical devices for cardiovascular medicine and translational research on vascular biology and myocardial regeneration.
Show Less
![](https://rutherford-public-images.imgix.net/speakers/avatars/d3c4adfe8e722054f44236e98958775e.png?crop=faces&fit=crop&h=96&w=96)
Rasha Al-Lamee
Dr Rasha Al-Lamee is an Interventional Cardiology Consultant at Imperial College Healthcare NHS...
Read MoreDr Rasha Al-Lamee is an Interventional Cardiology Consultant at Imperial College Healthcare NHS Trust in London, UK. Dr Al-Lamee’s research interests are complex coronary intervention, coronary physiology and invasive intravascular assessment. She designed, conducted and led the ORBITA trial and is the lead author of the primary publication in The Lancet. At Imperial College, she is actively involved in the development and recruitment for a number of multi-centre clinical trials. Dr Al- Lamee has over 40 peer-reviewed publications and has presented at international Cardiology conferences worldwide throughout her clinical career. She studied at the University of Oxford and University College London. She went onto complete her training as a junior doctor on the Barts and the London Medical rotation before being appointed as a Specialist Registrar on the North West London Cardiology rotation in 2006. Dr Al-Lamee has twelve years of Cardiology experience and completed three years of Interventional Fellowship training at Hammersmith Hospital in London. She also spent a year training as an Interventional Fellow under the supervision of Professor Antonio Colombo in Milan. She completed specialist training in Cardiology in 2013.
Show Less![](https://rutherford-public-images.imgix.net/speakers/avatars/fd86466d7df680cd7deda6b49ba62396.png?crop=faces&fit=crop&h=96&w=96)
David Kandzari
Doctor Kandzari is Director of Interventional Cardiology, Piedmont Heart Institute and Chief...
Read MoreDoctor Kandzari is Director of Interventional Cardiology, Piedmont Heart Institute and Chief Scientific Officer, Piedmont Healthcare. He specializes in interventional cardiology, peripheral arterial disease and cardiovascular medicine.
Show Less![](https://rutherford-public-images.imgix.net/speakers/avatars/f45762f9346629d7c471ea8f31592a47.jpg?crop=faces&fit=crop&h=96&w=96)
Felix Mahfoud
Professor Felix Mahfoud is an Associate Professor and senior physician of Internal Medicine and...
Read MoreProfessor Felix Mahfoud is an Associate Professor and senior physician of Internal Medicine and Cardiology at Saarland University Hospital, and Affiliate/Visiting Professor Harvard-MIT Biomedical Engineering, Institute of Medical Engineering and Science, Cambridge, US. Professor Mahfoud completed training in Cardiology and Interventional Cardiology at the Department for Internal Medicine III, Saarland University Hospital, Germany in 2014. Since 2017, he has served as Vice Chairman of the ‘Working Group on Interventional Hypertension Treatment’ for the European Society of Hypertension, and as a Committee Member of the 2018 Hypertension Guidelines.
Show Less![](https://rutherford-public-images.imgix.net/speakers/avatars/0889c7780b34b346156ca2df219ee5be.jpg?crop=faces&fit=crop&h=96&w=96)
Atul Pathak
A consultant cadiologist at Clinique Pasteur, European excellence center for Hypertension,...
Read MoreA consultant cadiologist at Clinique Pasteur, European excellence center for Hypertension, Toulouse, France. Features in 35 videos on Wondr Medical. Atul Pathak generally speaks on Hypertension and Renal Denervation (RDN).
Show Less![](https://rutherford-public-images.imgix.net/speakers/avatars/91025a32f3ccd331c43c97370ccbbea4.png?crop=faces&fit=crop&h=96&w=96)
Andrew Sharp
Dr Sharp qualified from Edinburgh Medical School in 1998. He was appointed as a Consultant...
Read MoreDr Sharp qualified from Edinburgh Medical School in 1998. He was appointed as a Consultant Cardiologist at the Royal Devon and Exeter Hospital in 2011 and Honorary Associate Professor by the University of Exeter in 2018 before moving to the University Hospital of Wales in the summer of 2019. He conducted his early training at the Royal Infirmary of Edinburgh, before moving to London for his senior clinical training. He completed the prestigious Milan-Imperial Interventional Cardiology Fellowship programme, having spent a year in San Raffaele and Columbus Hospitals, Milan, Italy, under the tutelage of Professor Antonio Colombo. He also spent three years training in interventional cardiology at St Mary’s Hospital and The Hammersmith Hospital (Imperial College Hospitals) in London. Dr Sharp was awarded an MD postgraduate research degree from the University of Edinburgh for his work on the hypertensive heart and led a large research programme at the Royal Devon and Exeter Hospital, which he is now establishing in Wales. He has been Principal Investigator in more than 30 ethically-approved research trials since 2012 and has published extensively. He has an international reputation for leading the development of device-based treatments for hypertension (in particular that of renal denervation) and pulmonary embolism, as well as the advancement of intracoronary imaging and physiology.
Show Less![](https://rutherford-public-images.imgix.net/speakers/avatars/988b048864bcdfe384f3951e32f13c00.jpg?crop=faces&fit=crop&h=96&w=96)
Faisal Shariff
Prof Faisal Sharif is Professor in Translational Cardiovascular Medicine and Innovation at NUI,...
Read MoreProf Faisal Sharif is Professor in Translational Cardiovascular Medicine and Innovation at NUI, Galway and a consultant Interventional Cardiologist for Galway University Hospitals. His research focuses on medical devices for cardiovascular medicine and translational research on vascular biology and myocardial regeneration.
Show Less